EP0759036A1 - Molecules immuno-interactives i - Google Patents

Molecules immuno-interactives i

Info

Publication number
EP0759036A1
EP0759036A1 EP95910971A EP95910971A EP0759036A1 EP 0759036 A1 EP0759036 A1 EP 0759036A1 EP 95910971 A EP95910971 A EP 95910971A EP 95910971 A EP95910971 A EP 95910971A EP 0759036 A1 EP0759036 A1 EP 0759036A1
Authority
EP
European Patent Office
Prior art keywords
antibody
molecule
nyk
animal
immunointeractive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95910971A
Other languages
German (de)
English (en)
Other versions
EP0759036A4 (fr
Inventor
Andrew Frederick Wilks
Steven Alan Stacker
Robert Brenchley Oelrichs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of EP0759036A1 publication Critical patent/EP0759036A1/fr
Publication of EP0759036A4 publication Critical patent/EP0759036A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to immunointeractive molecules to an animal growth factor receptor and, more particularly, to animal neuroepithelial kinase/fetal liver kinase-1 receptor (NYK/flk-1).
  • the immunointeractive molecules provide the basis for new therapeutic and diagnostic agents which can be used, for example, in the treatment, prophylaxis and diagnosis of an angiogenic-dependent phenotype.
  • Angiogenesis is the formation of new blood vessels from those which preexist within the body (1). It is of fundamental importance for the development of the embryo and a number of roles in post-natal life (e.g. wound healing, tissue regeneration, cyclical growth of the corpus luteum and endometrium). Angiogenesis is also important in a number of pathological conditions including the growth of solid tumours (1). Recent studies have suggested that the acquisition of an angiogenic- dependent phenotype is a key factor in the development of metastasis.
  • PCR polymerase chain reaction
  • VEGF has a mitagenic effect on endothelial cells but is also a potent mediator of vascular permeability.
  • VEGF has in recent studies been shown to play a role in the hypoxia induced angiogenesis seen in a glioma model suggesting that VEGF may play a role in mediating angiogenesis in other tumour systems (6).
  • Other studies have shown that anti- VEGF monoclonal antibodies have an anti-tumour effect in vivo (7).
  • VEGF2R NYK receptor extracellular domain
  • These antibodies are useful in the development of a new range of therapeutic molecules such as agonists and antagonists of the NYK-VEGF interaction as well as a range of diagnostic agents capable of, for example, detecting normal or mutated NYK receptors, receptor expression on a cell surface and/or receptor-ligand interaction.
  • One aspect of the present invention provides an immunointeractive molecules capable of binding or otherwise associating with an animal NYK/flk-1 receptor extracellular domain.
  • the animal is a mammal such as a human or murine animals.
  • the immunointeractive molecule is a polyclonal or monoclonal antibody.
  • Another aspect of the present invention is directed to a diagnostic agent comprising an immunointeractive molecule capable of binding or otherwise associating with an animal NYK/flk-1 receptor extracellular domain.
  • the immunointeractive molecule is an antibody labelled with a reporter molecule.
  • Yet another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising an immunointeractive molecule as contemplated above together with one or more pharmaceutically acceptable carriers and/or diluents.
  • Still another aspect of the present invention provides a method for treating an angiogenic-dependent phenotype or disease condition resulting therefrom in a mammal, said method comprising administering to said mammal an effective amount of an immunointeractive molecule capable of binding or otherwise associating with an animal NYK/flk-1 receptor extracellular domain.
  • the method is particularly useful in the treatment of metastasis.
  • a further aspect of the present invention is the use of the subject interactive molecules to treat metastases by targeting isotypes such as 125 I and 131 I.
  • Figure 1 is a representation of the FLAGTM linker oligonucleotides which encode the sequence of the FLAGTM marker peptide with Bglll compatible ends for ligation into the mutant NYK receptor cDN A containing the Bglll site at the predicted extracellular/transmembrane junction.
  • FIG. 2 (A) is a schematic representation showing that an in frame Bglll site was introduced into the NYK cDNA clone at the extracellular/transmembrane junction using site directed mutagenesis.
  • the FLAGTM linker oligonucleotides were ligated into Bglll site and ligated plasmids selected by restriction enzyme digest with CM.
  • the selected clones were then transiently transfected into COS cells and shown to produce a protein of the predicted size for NYK-EX-FLAGTM.
  • Figure 3 is a photographic representation showing that NYK-EX-FLAGTM was purified from the conditioned medium of CHO cells stably transfected with the pEE6- NYK-EX-FLAGTM construct by affinity chromatography on M2-gel.
  • NYK-EX- FLAGTM was eluted with 30 ⁇ g/ml of free FLAGTM peptide in 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.02% v/v Tween 20. Fractions (lO ⁇ l of 1000) were analysed by SDS-PAGE and silver staining. Molecular weight markers are indicated and are 200, 97, 69 and 45 kDa.
  • Figure 4A is a schematic representation of the soluble mutant forms of the NYK receptor extracellular domain.
  • Bglll sites were introduced at select sites within the receptor cDNA sequence to produce mutants which encode truncated versions of the NYK receptor.
  • These mutants were then ligated into the expression vector AP-TAG-1 to produce fusion proteins which had Ig-like domains of NYK ligated to secreted alkaline phosphatase.
  • the mutant forms are D1-D2-AP (domains 1 and 2 coupled to alkaline phosphatase), D1-D2-D3- AP, D1-D5-AP and D1-D7-AP.
  • Figure 4B is a photographic representation showing immunoprecipitation of the NYK receptor domain mutants.
  • NIH-3T3 cells transfected with the D1-D2, Dl- D2-D3, D1-D5 and D1-D7 domain constructs subcloned into the AP-TAG-1 vector were biosynthetically labelled for 16 hours with 35 S-Cys/Met.
  • Supematants from these cells were immunoprecipitated with either 10 ⁇ l of Rabbit Ig-Sepharose, anti- AP-Sepharose, 4H3-Sepharose or 3B6-Sepharose beads.
  • One aspect of the present invention provides an immunointeractive molecule capable of binding or otherwise associating with an animal NYK/flk-1 receptor, and in particular, the extracellular domain of such a receptor.
  • the immunointeractive molecules are in the form of antibodies such as polyclonal or monoclonal antibodies although monoclonal antibodies are preferred.
  • the present invention also extends to immunologically interactive fragments, parts, derivatives, homologues or analogues of these antibodies.
  • Such antibodies may be in isolated or purified form meaning that a composition comprises at least 25 % , more preferably at least 35%, even ' more preferably at least 45-50%, still more preferably at least 60-75% and even still more preferably at least 80-95% of the antibodies as determined by weight, immunoreactivity or other convenient means.
  • the antibodies may be present in the form of isolated culture supernatant, tissue extract, serum or whole blood or ascites fluid.
  • the animal NYK/flk-1 receptor is of mammalian origin such as from a human, livestock animal (e.g. cow, horse, sheep, goat or donkey), laboratory test animal (e.g. rat, mouse or rabbit), companion animal (e.g. dog or cat) or captive wild animal (e.g. dingo, fox, wild boar or kangaroo).
  • livestock animal e.g. cow, horse, sheep, goat or donkey
  • laboratory test animal e.g. rat, mouse or rabbit
  • companion animal e.g. dog or cat
  • captive wild animal e.g. dingo, fox, wild boar or kangaroo
  • the most preferred receptors are of human and laboratory test animal origin (e.g. rat or mouse).
  • the antibodies are polyclonal antibodies, they may be generated in any convenient host including a human, livestock animal, companion animal or captive wild animal as exemplified. Where the antibodies are monoclonal antibodies, they may be prepared in any convenient hybridoma such as of murine (e.g. rat or mouse) origin.
  • the receptor used to generate the antibodies may be the whole receptor such as in purified, partially purified or isolated form including in the form of isolated membrane preparations.
  • the receptor may also be produced by recombinant procedures or synthetic procedures or a combination thereof.
  • a fragment of the receptor is used which, in an even more preferred embodiment, is fused to a suitable carrier or marker molecule such as
  • FLAGTM protein FLAGTM protein.
  • An example of another carrier is alkaline phosphatase (AP).
  • Glutathione-S-transferase may also be used, although it may first require modification to facilitate induction of monoclonal antibodies.
  • GST Glutathione-S-transferase
  • the non-full length receptor comprises its extracellular domain.
  • the carrier molecule is FLAGTM or AP.
  • the resulting fusion molecule is then used to generate polyclonal or monoclonal antibodies which may undergo immunoadsorbent procedures to provide a composition of substantially, for example, extracellular domain-reactive receptor antibodies.
  • immunointeractive molecules is used herein in its broadest sense and includes antibodies, parts, fragments, derivatives, homologues or analogues thereof, peptide or non-peptide equivalents thereof and fusion molecules between two or more antibodies or between an antibody and another molecule.
  • the antibodies or other immunointeractive molecules may also be in recombinant or synthetic form.
  • the interactive molecules are antibodies
  • these may be generated in a number of different species such as humans, mice and rats. Accordingly , the present invention contemplates mutants and derivatives of the immunointeractive molecules, especially when such molecules are antibodies.
  • Mutants and derivatives of such antibodies include amino acid substitutions, deletions and/or additions. Furthermore, amino acids may be replaced by other amino acids having like properties, suchashydrophobicity, hydrophilicity, electronegativity, bulky side chains, interactive and/or functional groups and so on. Glycosylation variants and hybrid antibodies are also contemplated by the present invention. Amino acid substitutions are typically of single residues; insertions will usually be of the order of about 1-10 amino acid residues; and deletions will range from about 1-20 residues. Deletions or insertions preferably are made in adjacent pairs, i.e.: a deletion of 2 residues or insertion of 2 residues.
  • amino acid variants referred to above may readily be made using synthetic peptide techniques well known in the art, such as solid phase peptide synthesis and the like, or by recombinant DNA manipulations. Techniques for making substitution mutations at predetermined sites in DNA having known sequence are well known, for example through M13 mutagenesis. The manipulation of DNA sequences to produce variant proteins which manifest as substitutional, insertional or deletional variants are well known in the art.
  • recombinant or synthetic mutants and derivatives of the antibodies of the present invention include single or multiple substitutions, deletions and/or additions to any molecule associated with the ligand such as carbohydrates, lipids and/or proteins or polypeptides. Naturally occurring or altered glycosylated forms of the subject antibodies are particularly contemplated by the present invention.
  • Amino acid alterations to the subject polypeptide contemplated herein include insertions such as amino acid and/or carboxyl terminal fusions as well as intra- sequence insertions of single or multiple amino acids. Generally, insertions within the amino acid sequence will be smaller than amino or carboxyl terminal fusions, of the order of about 1 to 4 residues. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in the protein. Deletional variants are characterised by the removal of one or more amino acids from the sequence. Substitutional variants are those in which at least one residue in the sequence has been removed and a different residue inserted in its place. Such substitutions may be made in accordance with Table 1. TABLE 1
  • analogues and derivatives also extend to any functional chemical equivalents of the antibodies characterised by their increased stability and/or efficacy in vivo or in vitro.
  • the terms “analogue” and “derivatives” further extend to any amino acid derivative of the antibodies as described above.
  • Antibody analogues contemplated herein include, but are not limited to, modifications to side chains, incorporation of unnatural amino acids and/or derivatising the molecules and the use of crosslinkers and other methods which impose conformational constraints on the antibodies.
  • side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5 '-phosphate followed by reduction with NaBH 4 .
  • modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TN
  • the guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3- butanedione, phenylglyoxal and glyoxal.
  • the carboxyl group may be modified by carbodiimide activation via O- acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.
  • Sulphydryl groups may be modified by methods such as carboxymethylatiori with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbomoylation with cyanate at alkaline pH.
  • Tryptophan residues may be modified by, for example, oxidation with N- bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides.
  • Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.
  • Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethy lpyrocarbonate .
  • Examples of incorporating unnatural amino acids and derivatives during protein synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t- butylglycine, norvaline, phenylglycine, ormthine, sarcosine, 4-amino-3-hydroxy-6- methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids.
  • peptides could be conformationally constrained by, ' for example, incorporation of C a and N ⁇ - memylamino acids, introduction of double bonds between C a and C ⁇ atoms of amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.
  • the present invention extends to amino acid and/or chemical analogues of the subject antibodies having the identifying characteristics of being interactive with the extracellular domain of the NYK flk-1 receptor. Accordingly, reference herein to an antibody includes the naturally occurring molecule, recombinant, synthetic and analogue forms thereof and to any mutants, derivatives and human and non-human homologues thereof including amino acid and glycosylation variants.
  • the immunointeractive molecules of the present invention may be used to develop a new range of therapeutic and diagnostic agents.
  • the antibodies or fragments or derivatives thereof may act as antagonists and be useful, for example, in the treatment of angiogenic-dependent phenotype and disease conditions resulting therefrom (e.g. metastasis). They may also be used for screening for agonists useful, for example, where angiogenesis is to be promoted. Normal or mutated receptor structure or receptor expression can also be determined through immunoreactivity studies.
  • a method of detecting a NYK flk-1 receptor on a cell in a biological sample comprising contacting said sample with an immunointeractive molecule capable of binding to the extracellular domain of said NYK/flk-1 receptor immobilised to a solid support for a time and under conditions sufficient for an immunointeractive molecule- NYK/flk-1 complex to form and then detecting the presence of said complex.
  • the immunointeractive molecule in NYK/flk-1 complex is detected by contacting the complex with an antibody against the immunointeractive molecule with the antibody being labelled with a reporter molecule.
  • the immunointeractive molecule itself is labelled with a reporter molecule.
  • the immunointeractive molecules are generally antibodies and these, or antibodies directed against the immunointeractive molecules (e.g. anti-idotype antibodies), may be polyclonal or monoclonal antibodies. These are obtainable by immunisation of a suitable animal with the immunointeractive molecule (or NYK/flk-1 molecule), and either type is utilizable in the assay. The methods of obtaining both types of sera are well known in the art. Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of immunointeractive molecule or NYK/flk-1 preparation, or antigenic parts thereof, collecting serum from the animal, and isolating specific antibodies by any of the known immunoadsorbent techniques. Although antibodies produced by this method are utilisable in virtually any type of assay, they are generally less favoured because of the potential heterogeneity of the product.
  • the use of monoclonal antibodies in the above immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product.
  • the preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitised against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art. (See, for example Douillard and Hoffman, Basic Facts about Hybridomas, in Compendium of Immunology Vol H, ed. by Schwartz, 1981; Kohler and Milstein, Nature 256: 495-499, 1975; European Journal of Immunology 6: 511-519, 1976).
  • the presence of a NYK flk-1 receptor may be accomplished in a number of ways such as by Western blotting and ELISA procedures.
  • a wide range of immunoassay techniques are available as can be seen by reference to US Patent Nos. 4,016,043, 4, 424,279 and 4,018,653. These, of course, include both single-site and two-site or "sandwich" assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also include direct binding of a labelled antibody to a target.
  • Sandwich assays are among the most useful and commonly used assays and are particularly useful in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in one type of assay, an immunointeractive molecule is brought into contact with a biological sample comprising cells potentially carrying NYK/flk-1. After a suitable period of incubation, for a period of time sufficient to allow formation of an immunointeractive molecule-NYK flk-1 complex, an antibody specific to the immunointeractive molecule, labelled with a reporter molecule capable of producing a detectable signal, is then added and incubated allowing sufficient time for the formation of a tertiary complex.
  • any unreacted material is washed away, and the presence of the antibody bound to the immunointeractive molecule is determined by observation of a signal produced by the reporter molecule.
  • the results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of antibody binding molecule.
  • Variations on the forward assay include using an immunointeractive molecule labelled with a reporter molecule.
  • the immunointeractive molecule or cells may be immobilised onto a solid support. Suitable solid supports include glass or a polymer, the most commonly used polymers being cellulose, poly aery lamide, nylon, polystyrene, polyvinyl chloride or polypropylene.
  • the solid supports may be in the form of tubes, beads, discs of microplates, or any other surface suitable for conducting an immunoassay.
  • the binding processes are well known in the art and generally consist of cross-linking, covalently binding or physically adsorbing the molecules to the polymer.
  • reporter molecule is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative.
  • the most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chen ⁇ luminescent molecules.
  • an enzyme immunoassay an enzyme is conjugated to the immunointeractive molecule or an antibody thereto generally by means of glutaraldehyde or periodate. As will be readily recognised, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan.
  • Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta-galactosidase and alkaline phosphatase, amongst others.
  • the substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates which yield a fluorescent product rather than the chromogenic substrates noted above.
  • the enzyme-labelled antibody is added to the immunointeractive molecule-receptor complex, allowed to bind, and then the excess reagent is washed away.
  • an enzyme labelled immunointeractive molecule is used.
  • a solution containing the appropriate substrate is then added to the tertiary complex.
  • the substrate will react with the enzyme linked to the antibody/immunointeractive molecule, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of immunoreactive molecule which was present in the sample.
  • Reporter molecule also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.
  • fluorescent compounds such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity.
  • the fluorochrome- labelled antibody When activated by illumination with light of a particular wavelength, the fluorochrome- labelled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope.
  • Immunofluorescence and EIA techniques are both very well established in the art and are particularly useful for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.
  • the present invention also provides a pharmaceutical composition comprising an effective amount of an immunointeractive molecule capable of binding or otherwise associating with the extracellular domain of NYK flk-1 receptor and one or more pharmaceutically acceptable carriers and/or diluents.
  • the active ingredients of a pharmaceutical composition comprising the immunointeractive molecules are contemplated to exhibit excellent therapeutic activity, for example, in the treatment of angiogenic-dependent phenotype and disease conditions resulting therefrom, such as metastasis, in an amount which depends on the particular case. For example, from about 0.5 ⁇ g to about 20 mg per kilogram of body weight per day may be administered. Dosage regime may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • the active compound may be administered in a convenient manner such as by the oral, intravenous (where water soluble), intramuscular, subcutaneous, intranasal, intradermal or suppository routes or implanting (e.g. using slow release molecules).
  • the active ingredients which comprise the immunointeractive molecules may be required to be coated in a material to protect said ingredients from the action of enzymes, acids and other natural conditions which may inactivate said ingredients.
  • they will be coated by, or administered with, a material to prevent its inactivation.
  • the immunointeractive molecules may be administered in an adjuvant, co-administered with enzyme inhibitors or in liposomes.
  • Adjuvant is used in its broadest sense and includes any immune stimulating compound such as interferon.
  • Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether.
  • Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol.
  • Liposomes include water-in-oil-in- water emulsions as well as conventional liposomes.
  • the active compounds may also be administered parenterally or intraperitoneally.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for mjectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of superfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenoi, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
  • the active, compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
  • the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 1 % by weight of active compound.
  • compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit.
  • the amount of active compound in such therapeutically useful compositions in such that a suitable dosage will be obtained.
  • Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.5 ⁇ g and 2000 mg of active compound.
  • the tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring.
  • a binder such as gum tragacanth, acacia, corn starch or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint
  • tablets, pills, or capsules may be coated with shellac, sugar or both.
  • a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations and formulations.
  • pharmaceutically acceptable carrier and/or diluent includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.
  • the principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore disclosed.
  • a unit dosage form can, for example, contain the principal active compound in amounts ranging from 0.5 ⁇ g to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 0.5 ⁇ g to about 2000 mg/ml of carrier.
  • the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
  • the immunointeractive molecules used in a pharmaceutical composition are antibodies or mutants or derivatives thereof. Most preferably, the antibodies are monoclonal antibodies.
  • the present invention is further described by reference to the following non- limiting examples.
  • mice myeloma P3X63Ag8.653(NS-l) was maintained in Dulbecco's modified Eagle's medium supplemented with 10% v/v HI FBS, 5 mM L-glutamine, 50 ⁇ g/ml gentamycin, grown at 37°C in a humidified atmosphere of 10% v/v CO 2 .
  • Hybridomas were grown in supplemented DMEM plus 10 ⁇ g/ml of recombinant IL-6 (rIL-6) at all stages after removal from the hypoxanthine/aminopterin/thymidine (HAT) selection medium.
  • rIL-6 recombinant IL-6
  • NIH-3T3 cells transfected with the AP-TAG-1 constructs were selected in supplemented DMEM containing 700 ⁇ g/ml G418.
  • CHO cell lines were grown in Glasgow Minimal Essential Medium supplemented with 50 ⁇ g/ml gentamycin, non-essential amino acids, sodium pyruvate, glutamate and asparaginine, nucleosides and 25 mM methionine sulphoxide (MSX).
  • COS cells were maintained in RPMI-1640 medium with supplements at 37°C and 5% v/v CO 2 and transfected using the DEAE-dextran protocol (8).
  • EXAMPLE 2 Construction of Truncated Forms of the NYK Receptor To obtain constructs which would encode various portions of the NYK extracellular domain, site-directed mutagenesis was employed to generate specific inframe restriction enzyme sites within the clone.
  • the full length clone of the NYK/flk-1 receptor described by Oelrichs et al (2) was subcloned into the mammalian expression vector ⁇ cDNAl-amp (Invitrogen, San Diego, CA) using the BstXI restriction enzyme site. Single stranded DNA was generated using the Ml 3 origin of replication, and this DNA used as a template to make NYK cDNA containing specific enzyme sites. Inframe Bglll sites were introduced after the final beta strand of a given Ig-like domain to produce constructs which could then be ligated into the (5 ')HindIII- 3 ')BgIII site of the expression vector AP-TAG-1.
  • Bglll sites were introduced to produce constructs containing the two most N-terminal domains (D1-D2), the first three domains (D1-D2-D3), the first five domains (D1-D2-D3-D4-D5) or the entire extracellular domain (NYK-EX-D1-D7- AP).
  • Hindlll-BgUI fragments of these mutants were then ligated into the Hindlll- Bglll site of AP-TAG-1 to produce D1-D2-AP, D1-D2-D3-AP, D1-D5-AP, D1-D7- AP.
  • the resultant plasmids were co-transfected with pgk-neo into NIH-3T3 fibroblasts and selected by their ability to grow in 700 ⁇ g/ml G418.
  • Lines secreting the AP fusion proteins were selected using the conversion of the substrate PNPP (Southern Biotechnology Associates) which detects AP activity in the tissue culture supematants (9). Endogenous AP activity is reduced by heating the samples at 65° C for 10 minutes prior to assaying.
  • the mutant NYK receptor containing the Bglll site located at the junction of the extracellular domain and the transmembrane domain was used to ligate a oligonucleotide linker sequence encoding the FLAGTM marker peptide (IBI), an in frame stop codon, Bglll compatible ends and an internal Clal site.
  • IBI FLAGTM marker peptide
  • IBI 5'- GATCTGACTACAAGGACGACGACGATGACAAGTGAATCGATA-3' [SEQ ID NO:2], (N)Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-Term(C) [SEQ ID NO:l]).
  • the entire NYK cDNA was then transferred (5' XbaI-3' Xbal) into the Xbal site of the CHO cell expression vector.
  • This construct was transfected into CHO-K1 cells and positive clones selected in medium containing 25 mM (MSX). Expressing clones were selected by immunoprecipitation of 35 S-methionine labelled cells with anti- FLAGTM (M2) antibody gel.
  • a cDNA clone encoding the MW 165 amino acid form of VEGF was isolated using the polymerase chain technique from mouse lung cDNA library (6 week female C57BL CBA) [Stratagene, Cat #936307) in lambda 2APII vector. The fragment was subcloned into the vector pCDM ⁇ and used for transient expression in COS cells. Supernatents from these cells demonstrated vascular permeability in the Miles assay indicating that the clone was indeed functional. This fragment was removed by Xbal digest and subcloned into a CHO cell expression vector. COS cells were transiently transfected using the DEAE Dextran method as previously described. Supernatant' s were assayed on days 5 to 7 following transfection to determine VEGF activity.
  • NYK-D1-D7-FLAGTM was purified from the expended tissue culture supernatant of NYK-Dl-D7-FLAGTM-CHO by affinity chromatography on a M2 (anti- FLAGTM) gel (IBI). Supernatant (100 ml) was passed over the M2 column then subsequently washed with 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.02 v/v Tween 20; 50 mM TEA pH 10.0, 150 mM NaCl, 0.02% v/v Tween 20 (optional) and again with 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.02% v/v Tween 20.
  • Bound material was eluted with either 100 mM glycine-HCl pH 3.0 (neutralised in 1/10 volume 1M Tris-HCl pH 8.6) or 25 ⁇ g/ml FLAGTM peptide (N-Asp-Tyr-Lys-Asp-Asp-Asp-Asp- Lys-C [SEQ ID NO:l]) in 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.02% v/v Tween 20. Both of these elution techniques gave about 90-95% pure NYK-D1-D7- FLAGTM by SDS PAGE. For immunisations and coupling to the sensor chip these proteins were further purified by ion-exchange chromatography (MonoQ, HPLC 1090) to give a single homogenous species corresponding to NYK-FLAGTM).
  • HPLC purified NYK-FLAGTM (lmg) was coupled to Affi-Gel 10 beads using NHS chemistry. This affinity column was then used to isolate VEGF from CHO cell supematants.
  • NYK-D1-D7-FLAGTM (approx 10 ⁇ g) was used to immunise female Wistar rats on day 52 (i.p.), 28 (i.p.) and 3 (i.v. and i.p.) prior to fusion with the mouse myeloma P3X63Ag8.653 (NS-1).
  • NYK-D1-D7-FLAGTM was prepared for the first two i.p.
  • Monoclonal antibodies to the NYK extracellular domain were selected by screening the fusion on purified NYK-D1-D7-FLAGTM and tiel extracellular domain- FLAGTM by an enzyme immunoassay. Briefly, 96 well PVC microtitre plates were coated with either NYK-D1-D7-FLAGTM or rie2-EX-FLAGTM at a level previously determined by reactivity with an anti-FLAGTM antibody (M2) to give an equivalent signal. Hybridoma supematants were added and incubated for 2h at 4°C, followed by six washes with PBS/0.02% v/v Tween 20 (buffer).
  • Rat monoclonal antibodies were purified using the technique of Darby et al, (10). Briefly, FCS was depleted of bovine IgG by serial passage over a protein G Sepharose fast flow gel. The resulting bovine IgG depleted serum was used for the bulk culture of the rat hybridoma cell line. Cells were grown in roller bottles containing DMEM, 10% v/v IgG depleted FCS, 5 mM L-glutamine, 50 ⁇ g/ml gentamicin and 10 ⁇ g/ml recombinant IL-6 until expiration and the supernatant removed from the cellular debris. Rat IgG was subsequently purified by affinity chromatography on protein G-Sepharose and the yield assessed by OD 280 .
  • Antibodies were dialysed versus PBS for use in assays.
  • the antibodies were dialysed against 0.1M NaHCO 3 /0.5M NaCl and then conjugated at about 2mg of antibody per ml of beads.
  • Protein A purified rabbit Ig was also coupled to the Sepharose beads as a non- binding control.
  • Subconfluent monolayers of either NIH-3T3 fibroblasts or CHO-K1 cells transfected with the various NYK domain constructs were starved in Met Cys medium containing 5% v/v FCS, 5 mM L-glutamine and 50 ⁇ g/ml gentamycin for 0.5h prior to incubating with 100 ⁇ Ci 35 [S] cysteine/metWonine (Translabel, ICN) per 10 6 cells. After a 16 h incubation at 37 °C supematants were collected and used for immunoprecipitation analysis.
  • Supematants were incubated with 10 ⁇ l of anti- FLAGTM M2 affinity gel or 10 ⁇ l of 4H3-Sepharose or 3B6-Sepharose at 4°C with rotation for 2-4h.
  • Immunoprecipitates were washed three times with 10 mM Tris- HCl pH 8.0, 150 mM NaCl, 1 % v/v Triton X-100 and then twice with 10 mM Tris- HCl pH 8.0, 150 mM NaCl, 0.1% v/v Triton X-100 then 10 mM Tris-HCl pH 8.0.
  • Immunoprecipitates were boiled in 2 x SDS PAGE sample buffer and analysed by denaturing polyacrylamide gel electrophoresis.
  • NYK receptor a construct was produced containing the NYK extracellular domain fused in frame to the FLAGTM marker peptide. This was achieved by introducing a Bglll site at the junction of the extracellular domain and the transmembrane domain of the receptor by site-directed mutagenesis. An oligonucleotide linker sequence encoding the FLAGTM marker peptide, an in frame stop codon and having Bglll cut ends was then ligated into this site and successfully ligated plasmids selected by a Clal site within the liker sequence. Expression analysis in COS cells demonstrated a protein of the expected size which could be specifically immunoprecipitated by the M2 (anti-FLAGTM) gel. The construct was subcloned into the CHO cell expression vector pEE6 for large scale production of the NYK-EX-FLAGTM protein.
  • the NYK-EX-FLAGTM protein was purified from CHO cell supematants by affinity chromatography on M2 antibody gel and elution with the free FLAGTM peptide. Subsequent purification by ion-exchange chromatography removed the free peptide and other contaminants giving a single homogenous species of M w 120,000- 130,000 by SDS-PAGE which is consistent with the predicted size of the extracellular domain plus glycosylation. Rats were immunised with the NYK-EX-FLAGTM protein and upon achieving an appropriate response their spleen cells were fused with the mouse myeloma NS-1 using standard somatic cell hybridisation techniques.
  • Antibodies were selected on the basis of their reactivity to purified NYK-EX-FLAGTM compared to another fusion protein containing the extracellular domain of the tie! receptor ligated to the FLAGTM marker peptide. To determine if these antibodies could recognise the NYK extracellular domain, cell lines expressing the NYK-EX- FLAGTM and NYK-EX-AP were biosynthetically labelled with 35 S Cys-Met and used for immunoprecipitation experiments. Three monoclonal antibodies were shown to specifically immunoprecipitate the NYK-EX-FLAGTM and NYK-D1-D7AP protein indicating they recognise the native NYK extracellular domain.
  • the antibodies have also been shown to react with the NYK-EX-FLAGTM coupled to the optical biosensor; NYK on the biosensor chip is active in that it binds the 165 amino acid form of VEGF from CHO cell supematants. Characterisation of two of the monoclonal antibodies on domain mutants of the NYK extracellular region show that 4H3 and 3B6 immunoprecipitate the D1-D2-AP, D1-D2-D3-AP, D1-D5-AP and D1-D7-AP fusion proteins indicating that their binding sites are restricted to the two most N- te ⁇ ninal Ig-like domains.
  • pBOS-NYK-EpoR was then cotransfected into the factor-dependent pre-B cell line BA/F3 with the neomycin resistance plasmid.
  • the BA/F3 cell lines is dependent on the presence of IL-3/GM-CSF for growth; removal of these factors results in rapid cell death with 24-48 h.
  • Cells were selected in DMEM, 10% HI FCS, 50 ⁇ g/ml gentamycin, 5 mM L-glutamine and 1.2 mg/ml G418 growth medium. Individual clones growing after 7-14 days were picked and expanded in liquid culture.
  • NYK-EpoR expressing colonies were selected by two procedures: (i) immunoprecipitation of 35 S-met/Cys/labelled receptors with anti-NYK mAbs and analysis by SDS-PAGE; (ii) stimulation of the cell line with ligand (VEGF).
  • VEGF ligand
  • the assay therefore specifically detects interactions of the NYK extracellular domain and its ligand VEGF, and is therefore useful for detection and evaluation of substances that may modulate this interaction, or detection and evaluation of inhibitors of such modulatory substances.
  • Transfected or untransfected BA/F3 cells were removed from WEHI3D conditioned medium, washed twice in PBS and resuspended in medium containing 5 ng/ml of VEGFies.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des molécules présentant une immuno-interactivité avec le récepteur du facteur de croissance animale et, en particulier, le récepteur kinase neuroépithéliale/kinase-1 hépatique f÷tale (NYK/flk-1). Ces molécules immuno-interactives constituent la base de nouveaux agents thérapeutiques et diagnostiques, utiles pour le traitement, la prophylaxie et le diagnostic du phénotype angiogéno-dépendant.
EP95910971A 1994-02-10 1995-02-09 Molecules immuno-interactives i Withdrawn EP0759036A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPM3793A AUPM379394A0 (en) 1994-02-10 1994-02-10 Immunointeractive molecules - i
AUPM3793/94 1994-02-10
PCT/US1995/001727 WO1995021865A1 (fr) 1994-02-10 1995-02-09 Molecules immuno-interactives i

Publications (2)

Publication Number Publication Date
EP0759036A1 true EP0759036A1 (fr) 1997-02-26
EP0759036A4 EP0759036A4 (fr) 1999-12-01

Family

ID=3778411

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95910971A Withdrawn EP0759036A4 (fr) 1994-02-10 1995-02-09 Molecules immuno-interactives i

Country Status (5)

Country Link
EP (1) EP0759036A4 (fr)
JP (1) JPH09509414A (fr)
AU (1) AUPM379394A0 (fr)
CA (1) CA2182682A1 (fr)
WO (1) WO1995021865A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
KR19980701950A (ko) * 1994-12-23 1998-06-25 에드워드 에이. 맥더모 2세, 로이드 제이. 오울드 분석, 리셉터 단백질 및 리간드
CA2231400A1 (fr) 1995-09-08 1997-03-13 Genentech, Inc. Proteine apparentee au vegf
WO1997017442A1 (fr) 1995-11-08 1997-05-15 Immunex Corporation Proteine de liaison flk-1
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
AU2299099A (en) * 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
US20070036795A1 (en) 2003-06-09 2007-02-15 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010136A1 (fr) * 1991-11-15 1993-05-27 The Trustees Of Princeton University Recepteurs de cellules souches hematopoietiques totipotentes et leurs ligands
WO1994010202A1 (fr) * 1992-10-28 1994-05-11 Genentech, Inc. Antagonistes du facteur de croissance des cellules endotheliales vasculaires
WO1994011499A1 (fr) * 1992-11-13 1994-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Flk-1 UTILISE COMME RECEPTEUR POUR FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE
WO1995021868A1 (fr) * 1994-02-10 1995-08-17 Imclone Systems Incorporated Anticorps monoclonaux specifiques des recepteurs vegf et leurs d'utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32833E (en) * 1982-03-01 1989-01-17 President And Fellows Of Harvard College Screening vaccines and immunization process
US4683295A (en) * 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010136A1 (fr) * 1991-11-15 1993-05-27 The Trustees Of Princeton University Recepteurs de cellules souches hematopoietiques totipotentes et leurs ligands
WO1994010202A1 (fr) * 1992-10-28 1994-05-11 Genentech, Inc. Antagonistes du facteur de croissance des cellules endotheliales vasculaires
WO1994011499A1 (fr) * 1992-11-13 1994-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Flk-1 UTILISE COMME RECEPTEUR POUR FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE
WO1995021868A1 (fr) * 1994-02-10 1995-08-17 Imclone Systems Incorporated Anticorps monoclonaux specifiques des recepteurs vegf et leurs d'utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROCKWELL, P. ET AL: "In vitro neutralization of vascular endothelial growth factor activation of FLK - 1 by a monoclonal antibody." MOLECULAR BIOLOGY OF THE CELL, (1994) VOL. 5, NO. SUPPL., PP. 383A. MEETING INFO.: THIRTY-FOURTH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY SAN FRANCISCO, CALIFORNIA, USA DECEMBER 10-14, 1994 , XP002116505 *
See also references of WO9521865A1 *

Also Published As

Publication number Publication date
JPH09509414A (ja) 1997-09-22
EP0759036A4 (fr) 1999-12-01
CA2182682A1 (fr) 1995-08-17
WO1995021865A1 (fr) 1995-08-17
AUPM379394A0 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
WO1995021866A1 (fr) Molecule immuno-interactive se liant au domaine extracellulaire du recepteur tie2/tek
US6362325B1 (en) Murine 4-1BB gene
JPH02215385A (ja) インターロイキン４レセプター
US20120164660A1 (en) Method for using a diagnostic agent which includes a calcium binding protein assay reagent and assay method for calcium binding protein
JP3223260B2 (ja) Ｔ細胞増殖促進因子
IE902562A1 (en) Antagonists of gm-csf derived from the carboxyl terminus
EP0759036A1 (fr) Molecules immuno-interactives i
EP0731166A2 (fr) Nouvelles protéines liant le calcium
EP0625990B1 (fr) Complexes de glycoproteines et glycoproteines
US5902584A (en) Antibodies which bind the G-CSF receptor extracelluar domain and methods of treatment
JPH03164183A (ja) 脳由来の膜蛋白質発現系
EP0749445A1 (fr) Anticorps de fixant au domaine extracellulaire du recepteur du facteur de croissance des colonies de granulocytes g-csf et procedes de traitement
AU689231B2 (en) Immunointeractive molecules-I
US6218516B1 (en) Antibodies specific for the extracellular domain of NYK/flk-1 protein and uses thereof
JP2004512026A (ja) 高親和性可溶性インターロイキン−１８受容体
JP3519096B2 (ja) モノクローナル抗体、ハイブリドーマおよびそれらの用途
EP1156063A1 (fr) Anticorps contre le récepteur pour le facteur stimulant les colonies de granulocytes
AU689232B2 (en) An immunointeractive molecule which binds the (TIE)2/TEK receptor extracellular domain
AU695001B2 (en) Granulocyte colony stimulating factor receptor G-CSF-R interactive molecule
US6297361B1 (en) Use of histidine decarboxylase immunoreactivity to detect human cancer
US6387875B1 (en) Method of use for murine leukaemia inhibitory factor-binding protein (mLBP)
EP1367123A1 (fr) Neurotonine et utilisation
US5786451A (en) 23 Kd human retinal CAR antigen
JP3232415B2 (ja) モノクローナル抗体，その製造法および用途
KR19990087793A (ko) 러크-8로 표시된 싸이토킨

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960905

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991013

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010510

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010921